First Look Analysts Research Calls for Thursday, January 5
This report was sent to Briefing.com subscribers earlier today. Upgrades: > Cullen/Frost (CFR) upgraded to Buy from Neutral at BofA Securities; tgt $155 > FibroGen (FGEN) upgraded to Buy from Neutral at BofA Securities; tgt raised to $27 > Interpublic…
This report was sent to Briefing.com subscribers earlier today.
Upgrades:
> Cullen/Frost (CFR) upgraded to Buy from Neutral at BofA Securities; tgt $155
> FibroGen (FGEN) upgraded to Buy from Neutral at BofA Securities; tgt raised to $27
> Interpublic (IPG) upgraded to Neutral from Underperform at BofA Securities; tgt raised to $36
> Olin (OLN) upgraded to Overweight from Equal Weight at Barclays; tgt raised to $65
> Group of America (RGA) upgraded to Outperform from In-line at Evercore ISI; tgt raised to $167
Downgrades:
> Pearson Plc (PSO) downgraded to Underperform from Neutral at BofA Securities
> PNC (PNC) downgraded to Underperform from Neutral at BofA Securities; tgt raised to $160
> Prudential Plc (PUK) downgraded to Underperform from Neutral at Exane BNP Paribas
Others:
> Adaptimmune Therapeutics (ADAP) initiated with a Buy at EF Hutton; tgt $15
> Adaptive Biotechnologies (ADPT) initiated with a Sector Outperform at Scotiabank; tgt $15
> Allogene (ALLO) initiated with a Buy at EF Hutton; tgt $15
> Amylyx Pharmaceuticals (AMLX) initiated with a Buy at BofA Securities; tgt $50
> Atara Biotherapeutics (ATRA) initiated with a Buy at EF Hutton; tgt $25
> Bicycle Therapeutics (BCYC) initiated with a Buy at EF Hutton; tgt $55
> BioAtla (BCAB) initiated with a Buy at EF Hutton; tgt $25
> Bionano Genomics (BNGO) initiated with a Sector Outperform at Scotiabank; tgt $4
> Century Therapeutics (IPSC) initiated with a Buy at EF Hutton; tgt $18
> CRISPR Therapeutics (CRSP) initiated with a Buy at EF Hutton; tgt $75
> Fate Therapeutics (FATE) initiated with a Buy at EF Hutton; tgt $16
> G1 Therapeutics (GTHX) initiated with a Buy at EF Hutton; tgt $35
> Merus (MRUS) initiated with a Buy at EF Hutton; tgt $35
> Pacific Biosciences (PACB) initiated with a Sector Outperform at Scotiabank; tgt $12
> Rain Oncology (RAIN) initiated with a Buy at EF Hutton; tgt $16
> Replimune (REPL) initiated with a Buy at EF Hutton; tgt $60
> Twist Bioscience (TWST) initiated with a Sector Outperform at Scotiabank; tgt $33
> Veracyte (VCYT) initiated with a Sector Outperform at Scotiabank; tgt $33
Contact [email protected] for any questions or corrections.
Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.
He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.